Press Releases Keyword Search Year None20232022202120202019201820172016201520142013 May 18, 2023 Editas Medicine Reports Inducement Grant to New Chief Financial Officer May 16, 2023 Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer May 11, 2023 Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress May 5, 2023 Editas Medicine Announces First Quarter 2023 Results and Business Updates May 1, 2023 Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data May 1, 2023 Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events April 27, 2023 Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease April 13, 2023 Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director March 8, 2023 Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer February 22, 2023 Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates Pagination Current page 1 Page 2 Next page next › Last page last »
May 11, 2023 Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
May 1, 2023 Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
May 1, 2023 Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
April 27, 2023 Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
April 13, 2023 Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
March 8, 2023 Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
February 22, 2023 Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
